Despite tone, DTC ads are ‘useful’, Wyeth’s Essner says

Share this article:

Wyeth's chief executive Robert Essner said that although he does not like the tone of some DTC advertising, the method is helpful in educating consumers about certain medical conditions.
"I think, overall, direct-to-consumer advertising is useful. I think it alerts patients to the possibility that treatment is available for them. When it encourages them to see their doctor, it works in everybody's interest." Essner said in an interview appearing in today's edition of USA Today.
Essner added, "I don't like the tone of some of the ads, but I think giving consumers as much information as possible about the choices that they can make with their doctor is a very good thing for the health care system." In 2004, Wyeth ranked 13 among the top 20 companies by DTC spending, with $79.3 million spent, according to TNS Intelligence.
Essner made the comments during an interview discussing recent company growth following Wyeth's posting of a 44 percent gain in first-quarter net income last month.
 "Some of our major brands, like Effexor, an antidepressant, and Protonix (for heartburn), continue to grow." Essner said. "There was outstanding growth from Enbrel, a remarkable drug for rheumatoid arthritis and psoriasis. Prevnar, our pneumococcal vaccine, is also doing well and was the first vaccine ever to top the $1 billion mark in annual sales last year. Rapamune, our drug for organ transplantation, is doing well. And we're hoping an important drug called Tygacil, which is a new kind of antibiotic, will add to our growth in the second half."

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Illumina inks deal with J&J, AstraZeneca, Sanofi

The goal is to develop companion diagnostics to match patients with cancer treatments.

Abbott deal highlights inversion inaction

Political furor over the recent spate of tax inversions is having little influence on how the government chooses its partners.

Allergan reported to seek out Salix deal

The Wall Street Journal says the deal would add "another layer of intrigue" to the Allergan-Valeant hostilities.